How Thymosin Beta-4 Promotes Cell Migration
TB-500 / Thymosin Beta-4
42% Faster Re-epithelialization
Topical application of thymosin beta-4 increased wound re-epithelialization by 42% at 4 days and up to 61% at 7 days post-wounding in a dermal wound model.
Malinda et al., Journal of Investigative Dermatology, 1999
Malinda et al., Journal of Investigative Dermatology, 1999
View as imageWhen skin is cut, the first thing cells at the wound edge need to do is move. To move, they reorganize their cytoskeleton, the internal scaffolding made of actin filaments that gives cells their shape and propulsion. Thymosin beta-4 (TB4) is the protein that makes this reorganization possible. It sequesters monomeric G-actin, maintaining a ready pool that cells can rapidly polymerize into filaments when migration signals arrive. Without this pool, wound-edge cells cannot extend the lamellipodia (sheet-like projections) they need to crawl toward damaged tissue. For the complete overview of thymosin beta-4 research, see the pillar article on TB-500 and what the research shows.
This article explains the molecular steps between TB4 binding G-actin and a wound closing faster.
Key Takeaways
- TB4 binds G-actin through its LKKTET motif, capping the barbed end to prevent spontaneous polymerization and maintaining a reserve pool for rapid deployment (Ying et al., Current Protein & Peptide Science, 2023)
- When injury occurs, signaling cascades liberate G-actin from the TB4 pool, enabling directed polymerization at the leading edge of migrating cells
- TB4 activates integrin-linked kinase (ILK) and Akt2, increasing metalloproteinase production and laminin-332 synthesis for cell adhesion and migration
- In chronic granulomatous wounds, TB4 promoted repair through HIF-1a stabilization and autophagy activation (Renga et al., Nature Communications, 2019)
- Engineered tandem thymosin peptide with dual G-actin binding domains showed enhanced corneal wound healing over single TB4 (Nguyen et al., IOVS, 2025)
- TB4 promotes angiogenesis in ischemic tissue by activating Notch signaling and VEGF pathways (Lv et al., Molecular Medicine Reports, 2020)
Step 1: G-Actin Sequestration
Every nucleated cell in the body contains TB4. Intracellular concentrations reach 100-500 micromolar, making it one of the most abundant peptides in the cytoplasm. At these concentrations, TB4 binds roughly half of all unpolymerized actin monomers (G-actin), preventing them from spontaneously assembling into filaments (F-actin).
The binding is specific. TB4 wraps around G-actin in an extended conformation, contacting the barbed end of the monomer through its conserved LKKTET motif. This prevents the monomer from adding to the fast-growing end of actin filaments.[1] The result is a large intracellular buffer of ready-to-use actin. Without TB4, cells would have to synthesize new actin or wait for existing filaments to disassemble before they could build the structures needed for movement. With TB4, the raw material is already in place.
This sequestration is not permanent. When profilin (another actin-binding protein) is activated by cell signaling, it competes with TB4 for G-actin binding, releasing monomers from the TB4 pool. Profilin then channels these monomers to the barbed ends of growing filaments, accelerating polymerization specifically at the leading edge of the cell where movement is occurring. The TB4/profilin exchange is the molecular switch that converts a stored pool into directed motion.[1]
Scheller et al. (2022) demonstrated that TB4's role in actin dynamics extends beyond wound healing. In platelet function, TB4 controls the G-actin/F-actin balance required for platelet shape change and thrombus formation. Platelet-specific deletion of TB4 in mice disrupted actin dynamics, impaired platelet spreading, and reduced thrombus stability, confirming that TB4's actin-buffering function is essential across multiple cell types, not just wound-edge keratinocytes.[2]
Step 2: Directed Cell Migration
Actin polymerization at the leading edge is necessary but not sufficient for wound closure. Cells also need adhesion to the extracellular matrix, directional signaling, and degradation of matrix barriers. TB4 contributes to all three.
Integrin-linked kinase and Akt activation
TB4 binds integrin-linked kinase (ILK) at the cell's lamellipodia, the thin, sheet-like projections that extend in the direction of movement. This binding activates Akt2, a kinase that promotes cell survival and migration through multiple downstream targets. Akt2 activation increases production of matrix metalloproteinases (MMPs), enzymes that degrade extracellular matrix proteins to clear a path for migrating cells.[1]
Laminin-332 synthesis
TB4 upregulates synthesis of laminin-332, a heterotrimeric glycoprotein that serves as both an adhesion substrate and a migration signal for epithelial and endothelial cells. Keratinocytes (the cells that form the outer skin layer) use laminin-332 as a track to crawl across the wound bed. By increasing laminin-332 production, TB4 builds the road that cells need to reach the wound site.
Purinergic signaling in corneal migration
In corneal epithelial cells, Yang et al. (2020) identified an additional migration pathway. TB4-mediated cell migration involves purinergic signaling through P2Y receptors, which are activated by extracellular ATP released at wound sites. This purinergic component links TB4's migration-promoting effects to the damage-associated molecular pattern (DAMP) signaling that occurs when cells are injured and release their intracellular ATP.[3] The corneal epithelium is a clinically relevant model because it heals rapidly and because TB4-based eye drops (RGN-259) are in Phase 3 clinical trials for neurotrophic keratopathy.
Step 3: Angiogenesis
New blood vessels must form to supply oxygen and nutrients to healing tissue. TB4 promotes angiogenesis through multiple pathways.
Lv et al. (2020) tested TB4 in a critical limb ischemia mouse model. TB4 treatment induced angiogenesis by activating the Notch signaling pathway and upregulating vascular endothelial growth factor (VEGF). In ischemic hind limbs, TB4-treated mice showed increased capillary density and improved blood flow recovery compared to controls.[4] The Notch pathway is particularly relevant because it controls endothelial tip cell specification, the process by which specific endothelial cells lead the formation of new vessel sprouts.
The actin-sequestering function connects directly to angiogenesis. Endothelial cells forming new blood vessels must migrate, proliferate, and organize into tubular structures. Each of these steps requires cytoskeletal reorganization. TB4's G-actin pool provides the raw material, while its ILK/Akt signaling promotes endothelial survival and MMP production for extracellular matrix remodeling.
Bjorklund et al. (2020) reviewed TB4's tissue repair effects in heart injury, noting that TB4's angiogenic properties contribute to cardiac repair by promoting formation of new coronary microvasculature in infarcted tissue. The review described TB4 as a "multi-faceted tissue repair stimulating protein" whose effects extend beyond any single mechanism.[5] For the complete cardiac repair evidence, see Thymosin Beta-4 and Cardiac Repair: Heart Tissue Research.
Step 4: Anti-Inflammatory and Autophagy Pathways
Wound healing involves inflammation (to clear debris and pathogens), proliferation (cell migration and division), and remodeling (matrix reorganization). TB4 influences all three phases but has particularly interesting effects on resolving inflammation and activating tissue repair.
Renga et al. (2019), published in Nature Communications, demonstrated that TB4 promotes repair in chronic granulomatous disease (CGD) through HIF-1a stabilization and autophagy activation.[6] CGD is an immunodeficiency where patients develop granulomas (chronic inflammatory lesions) because their neutrophils cannot produce the reactive oxygen species needed to kill certain pathogens. TB4 promoted healing in these chronic wounds by shifting the cellular response from persistent inflammation toward autophagy-mediated tissue repair.
HIF-1a (hypoxia-inducible factor 1-alpha) is a master regulator of the cellular response to low oxygen. Wounds are hypoxic environments, and HIF-1a stabilization activates genes involved in angiogenesis, glucose metabolism, and cell survival. TB4's ability to stabilize HIF-1a provides a molecular explanation for why it promotes healing specifically in hypoxic, damaged tissue rather than causing uncontrolled cell growth in healthy tissue.
The autophagy connection is equally relevant. Autophagy is the cellular recycling program that clears damaged organelles and protein aggregates. In chronic wounds, defective autophagy contributes to impaired healing. TB4's activation of autophagy through HIF-1a suggests it can restart stalled repair processes in wounds that have become chronically inflamed rather than healing.
Step 5: Beyond Actin: Axon Regeneration
TB4's influence on cell migration extends beyond wound healing into neural repair. Song et al. (2024) showed that TB4 promotes axon regeneration in zebrafish Mauthner neurons by facilitating actin dynamics.[7] After axotomy (nerve cutting), TB4 enhanced the formation of growth cones, the motile structures at the tip of regenerating axons that navigate toward their targets. Growth cones are driven by actin polymerization, and TB4's G-actin pool provides the substrate.
This neural regeneration data connects TB4's mechanism back to its fundamental role: it enables directed cell movement by ensuring that actin is available when and where cells need it. Whether the cell is a keratinocyte crawling across a wound, an endothelial cell sprouting a new blood vessel, or a neuron regrowing its axon, the underlying machinery is the same.
Engineering Better TB4: The Tandem Approach
Nguyen et al. (2025) published a study in Investigative Ophthalmology & Visual Science describing an engineered tandem thymosin peptide (tTB4) created by fusing two TB4 monomers. The resulting molecule has dual G-actin binding domains, theoretically doubling its actin-sequestering capacity.[8]
In corneal wound models, tTB4 promoted healing with enhanced efficacy compared to single TB4. The tandem design increased the local concentration of actin-buffering capacity at the wound site without requiring higher peptide doses. This engineering approach validates the actin-sequestration mechanism: if TB4's healing effects are driven by its ability to maintain G-actin pools, then doubling the binding capacity should proportionally improve outcomes. The tandem peptide data supports this prediction.
This has implications for clinical translation. If single TB4 is limited by its affinity for G-actin or its residence time at wound sites, engineered variants with enhanced binding properties could produce superior healing outcomes. The tandem approach also opens the possibility of creating tissue-specific TB4 variants by fusing the actin-binding domain with targeting peptides that home to specific wound types.
Wound Healing Kinetics: What the Numbers Show
The quantitative wound healing data comes primarily from animal models, but the consistency across tissue types strengthens the mechanistic argument. In dermal wound models, topical TB4 increased re-epithelialization by 42% at 4 days post-wounding and up to 61% at 7 days, compared to saline controls. Treated wounds also contracted at least 11% more than controls by day 7. These effects were dose-dependent, with higher concentrations producing faster closure.
The corneal healing data is particularly clean because the corneal epithelium heals exclusively through cell migration (unlike dermal wounds, which involve both migration and proliferation). In corneal wound models, TB4 accelerated epithelial sheet movement across the wound bed in a manner consistent with enhanced actin dynamics at the leading edge. The RGN-259 clinical program chose the cornea as a development target partly because it isolates the migration mechanism from confounding proliferative effects, making it a more direct test of the G-actin sequestration hypothesis.
In chronic wound contexts, TB4's effects are more complex. Chronic wounds (diabetic ulcers, pressure sores, venous stasis ulcers) often stall in the inflammatory phase and fail to transition to the proliferative phase. TB4's ability to activate autophagy through HIF-1a stabilization and to promote anti-inflammatory signaling may restart the healing cascade in these stalled wounds. Phase 2 clinical trials in pressure and stasis ulcers showed efficacy with no adverse events, though the sample sizes were small.
The First Human Safety Data
Wang et al. (2021) reported the first-in-human clinical data for TB4: a randomized, double-blind, single- and multiple-dose Phase 1 study establishing the safety and pharmacokinetics of recombinant human thymosin beta-4 in healthy volunteers.[9] The study confirmed that systemically administered TB4 is well-tolerated, with no serious adverse events at tested doses.
Phase 3 trials of TB4 as an ophthalmic solution (RGN-259) for neurotrophic keratopathy have completed, with published results showing 0.1% TB4 promoted rapid healing of persistent corneal epithelial defects and improved ocular comfort. The corneal application leverages TB4's migration-promoting effects in a tissue that heals entirely through epithelial cell migration, making it an ideal proof-of-concept for the actin-sequestration mechanism.
For how TB4 compares to BPC-157, another peptide studied for tissue repair, see TB-500 vs BPC-157: How Two Healing Peptides Compare. For TB4's effects on muscle tissue specifically, see TB-500 for Muscle Repair. For the corneal healing evidence in detail, see Thymosin Beta-4 and Corneal Healing.
The Bottom Line
Thymosin beta-4 promotes wound healing through a cascade that begins with G-actin sequestration and extends through directed cell migration, angiogenesis, anti-inflammatory signaling, and matrix remodeling. The LKKTET motif binds G-actin monomers, creating a pool that cells deploy for rapid cytoskeletal reorganization at wound edges. Downstream effects include ILK/Akt activation, laminin-332 synthesis, MMP production, Notch-mediated angiogenesis, and HIF-1a-driven autophagy. Human clinical data confirms safety, and Phase 3 corneal trials validate the mechanism in a migration-dependent healing model.